Remove 2028 Remove Communication Remove Hospitals
article thumbnail

Revolution Medicines partners Royalty Pharma on $2bn funding

Pharmaceutical Technology

The first tranche will be received by Revolution, following US Food and Drug Administration (FDA) approval of daraxonrasib to treat metastatic PDAC by January 2028. The debt facility portion consists of three tranches totalling up to $750m linked directly to daraxonrasib’s commercial milestones. Sign up for our daily news round-up!

article thumbnail

Merck agrees to acquire Verona Pharma for $10bn

Pharmaceutical Technology

Keytruda, which brought in $30bn in revenue in 2024, is approaching patent expirations set in 2028, and Merck is therefore intensifying efforts to restructure its portfolio, according to a report by Reuters. This agreement will enable the strong launch trajectory of this important medicine and provides value to Verona Pharma shareholders.”

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

RFK Jr axes vaccine advisory committee members

Pharmaceutical Technology

Without removing the current members, the current Trump administration would not have been able to appoint a majority of new members until 2028, RFK Jr wrote. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard.

article thumbnail

Reaching for the gold standard of lung cancer screening

pharmaphorum

In 2021, a pilot communications programme from AstraZeneca UK and the NHS was launched in four locations across England. The goal set out by the NHSE Long Term Plan is ambitions: to have three quarters of cancers diagnosed at an early stage by 2028. It exists in multiple areas across multiple organisations.

article thumbnail

Transforming medicines value: a collaborative, data-driven approach

Hospital Pharmacy Europe

With several high-cost biological medicines due to lose patent exclusivity by 2028, NHS England has identified a £1bn savings opportunity. In the Northeast and North Cumbria (NENC) region, which serves 3.2 million people, secondary care drug costs rose to £668m in 2024/25, increasing at an average rate of 10% annually.

article thumbnail

Overview of the Internet of Medical Things (IoMT) 

Viseven

What once felt like science fiction has become an everyday reality for patients, healthcare providers (HCPs), and hospitals. million in 2028, according to Statista. In-hospital devices help monitor medical equipment, resources, and patient flow to ensure high-quality patient care and effective management at healthcare organizations.